The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

46 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.EBI
Peking Union Medical College
Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein.EBI
Ibitecs, Cea
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.EBI
Bryn Mawr College
Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.EBI
Glaxosmithkline
 
Structure-directed discovery of an inhibitor of the binding of HIV GP120 to the CD4 receptorEBI
TBA
 
β-Lactam peptides as potential inhibitors of the HIV gp120-CD4 interactionEBI
TBA
Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor.EBI
University of Illinois At Urbana-Champaign
Rational Design of Sulfonyl-γ-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity.EBI
University of South Florida
Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.EBI
Lindsley F. Kimball Research Institute
Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.EBI
Tokyo Medical and Dental University
Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.EBI
University of Siena
Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.EBI
Moscow State University
Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics.EBI
University of Pennsylvania
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.EBI
Tokyo Medical and Dental University (Tmdu)
Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.EBI
Nankai University
Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.EBI
Cornell University
Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.EBI
Tokyo Medical and Dental University
Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity.EBI
University of Pennsylvania
Design and Biological Evaluation of EBI
Shenyang Pharmaceutical University
Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.EBI
Touro University-California
Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors.EBI
Instituto De Qu£Mica M£Dica (Iqm-Csic)
Overview of Recent Strategic Advances in Medicinal Chemistry.EBI
Shandong University
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.EBI
Duke University Medical Center
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.EBI
Beijing Institute of Pharmacology and Toxicology
Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.EBI
Renmin Hospital of Wuhan University
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.EBI
TBA
PCSK9 inhibitors and methods of use thereofBDB
Astrazeneca
Therapeutic compounds and uses thereofBDB
Kala Pharmaceuticals
Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of useBDB
Abbvie
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of painBDB
Array Biopharma
Benzofurans substituted with primary benzamide as HCV inhibitorsBDB
Bristol-Myers Squibb
Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor ß/d (PPARß/d) in the brain.BDB
Case Western Reserve University School of Medicine
Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombiBDB
Piramal Imaging
 
Synthesis of indole analogs as potent ß-glucuronidase inhibitorsBDB
Universiti Teknologi Mara
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis CBDB
Merck Sharp & Dohme
Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.BDB
Southern Research Institute
Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparationBDB
Boehringer Ingelheim International
Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.BDB
China Pharmaceutical University
Antimicrobial compoundsBDB
Monash University
Pharmaceutically active compounds as Axl inhibitorsBDB
Lead Discovery Center
Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism.BDB
Novartis
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3.BDB
Merck Research Laboratories